MedTrace Logo

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

NCT05244460 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-01-20

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

Conditions

  • Cannabis Hyperemesis Syndrome

Interventions

DRUG

Droperidol Injectable Product

Treatment

DRUG

Diphenhydramine

Treatment

Sponsors & Collaborators

  • Lake Erie College of Osteopathic Medicine

    collaborator OTHER

  • Mercy Health Ohio

    lead OTHER

Principal Investigators

  • Todd Bolotin, MD · Mercy Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2023-01-31
Completion
2023-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05244460 on ClinicalTrials.gov